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Syndrome Xdefines a group of patients who present with typical,
usually exertional angina pectoris and a normal coronary arterio-
gram. They often have a positive exercise test, but direct signs of
ischemia are detectable in only a minority of patients. Areduced
coronary vasodilative response to dipyridamole or pacing is
observed in such patients with or without a positive electrocardio-
graphic exercise test. It is proposed that patients with syndrome X
have a patchily distributed abnormal constriction of coronary
prearteriolar vessels not involved in metabolic autoregulation of
flow. An increased resistance of prearteriolar vessels can explain
the reduced coronary vasodilative response observed in these
patients, even when arterioles dilate maximally. Distal to the most
constricted arterioles a localized compensatory increase of aden-
osine concentration can cause angina even in the absence of
The term syndrome X was first used by Kemp (I) in his
editorial comment accompanying an article by Arbogast and
Bourassa (2), in which these authors compared the features
of a group of patients with angina and angiographically
normal coronary arteries (Group X) with those of a group of
patients with angina and coronary artery stenoses. Subse-
quently, the term became a label for patients with normal
coronary angiograms who present with typical exertional
angina pectoris.
Patients with typical angina pectoris severe enough to
justify coronary arteriography, who were subsequently
found to have normal coronary arteries, represented 15% of
those included in the Coronary Artery Surgery Study
(CASS) Registry (3). Opinions about the cause of chest pain
in the presence of normal coronary arteriograms differ
widely. Some authors (4) believe that an ischemic origin of
chest pain could be as low as 1%; others (5) suggest that
abnormal behavior of small coronary vessels indicative of a
cardiac origin of pain can be detected in >50% of these
patients. This divergence of opinion is unlikely to be settled
until the mechanisms by which small coronary vessel dys-
function causes myocardial ischemia and angina pectoris are
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ischemia because adenosine is an algogenic substance. Ischemia
can develop when myocardial metabolic demand exceeds blood
supply or when metabolic or pharmacologic arteriolar vasodila-
tion causes excessive reduction of pressure at the origin of the
arterioles and possibly prearteriolar collapse.
The more severe and confluent is the patchy prearteriolar
constriction, the more detectable become the signs of myocardial
ischemia. The proposed abnormal prearteriolar constriction could
be caused by lack of endothelium-derived relaxing factor flow-
mediated vasodilation, by abnormal nervous stimuli or by a
combination of these two mechanisms. However, the causes of
abnormal coronary prearteriolar constriction are not necessarily
the same in all patients.
(J Am Coll CardioI1991;17:499-506)
better understood. In this report. we review the character-
istics of these patients and propose a pathogenetic hypoth-
esis that could explain this clinical syndrome and orient
future research.
Clinical Features
Diagnostic criteria. In its broadest definition, the term
Syndrome X might include a spectrum of patients who
possibly have various cardiac or noncardiac causes of angina
pectoris. Only some of these patients consistently develop
angina during exercise stress testing, some with and others
without diagnostic ST segment changes. In some patients
but not in others, acute myocardial ischemia could be
demonstrated by measurements of coronary sinus lactate
production (6,7) or oxygen saturation (8), by regional myo-
cardial perfusion defects (9-13) or by regional ventricular
wall motion abnormalities during exercise testing or pacing
(9,14). However, on clinical grounds, patients who develop
detectable myocardial ischemia cannot be distinguished
from those who do not. In the attempt to include under the
label of syndrome X a more homogeneous group of patients.
a positive response to exercise testing (angina and ST
segment depression >1 mm) is often required as one of the
inclusion criteria (8,15,16). In patients with a positive exer-
cise test, Holter electrocardiographic (ECG) monitoring
shows episodes of transient ST segment depression indistin-
guishable from ischemic episodes observed in patients with
chronic stable angina and, as in patients with coronary artery
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disease, a large proportion of these transient episodes are
not preceded by changes of heart rate or occur at heart rates
lower than those observed during exercise (15).
Symptoms, a positive exercise test and episodes of tran-
sient ST segment depression during Holter monitoring may
persist over a period of several years (17-20). However,
even using strict inclusion criteria, recent careful studies
failed to show myocardial lactate production during pacing
(21), increases in pulmonary pressure during spontaneous
episodes of transient ST segment depression (16), abnormal-
ities of left ventricular wall motion as assessed by two-
dimensional echocardiography during dipyridamole testing
(22) or decreases in coronary sinus blood oxygen saturation
during atrial pacing (in 8 of 10 patients) (8). Conversely, the
majority of patients with syndrome X with and without
ischemic ECG changes during exercise testing seem to
exhibit an abnormally small increase in coronary flow in
response to dipyridamole or pacing (5,7,14,23), particularly
after ergonovine administration (23). In one study (24) of
patients with syndrome X, most without ischemic ECG
changes during exercise testing, an abnormal vasomotor
response in the forearm was also observed. Therefore,
although the adoption of stricter inclusion criteria such as
transient ischemic ST segment shifts during anginal pain
should considerably narrow the diagnostic field, the absence
of ECG changes during pain does not necessarily exclude a
cardiac origin of symptoms.
Distinguishing clinical features. The uncertainties about
the causes of the syndrome make the diagnosis of a cardiac
or noncardiac origin of the pain difficult. Patients with
syndrome X with or without ischemic ECG changes often
present some distinguishing clinical features not usually
observed in patients with critical epicardial coronary steno-
ses or spasm. To date, these features have not received
adequate consideration.
Even those patients who demonstrate transient ischemic-
like ECG changes exhibit a substantial discrepancy between
the presence of anginal pain, usually severe, and signs ofleft
ventricular dysfunction during pain, which are usually mild
or undetectable (16,22). This is in sharp contrast with the
frequent absence of pain despite the profound alterations of
left ventricular function consistently associated with tran-
sient ischemic ECG changes in patients with epicardial
coronary artery stenoses or spasm (25-27). Additionally,
patients with syndrome X often report a prolonged duration
of pain continuing for> 30 min after effort or emotion. In our
experience, occasional episodes of pain induced by effort or
emotion lasting>30 min were reported by 40% of 42 patients
with angina, a normal coronary arteriogram, no evidence of
epicardial coronary artery spasm and ischemic-like ECG
changes during exercise testing. The discrepancy between
the presence of anginal pain and the lack or scarcity of
objectively detectable myocardial ischemia suggests that
predominantly algogenic rather than ischemic stimuli oper-
ate in this syndrome. Thus, any pathogenetic hypothesis that
attempts to explain the reduced coronary flow response to
vasodilatory stimuli and the possible development of ische-
mia and angina in these patients should explain: 1) the
occurrence of angina and ischemic ST changes during efforts
of variable intensity and occasionally also at rest, as well as
the occurrence of angina after dipyridamole; and 2) the
presence and long duration of anginal pain with minimal or
no detectable ECG abnormalities and normal left ventricular
function.
Pathogenetic Hypothesis
Role of small vessel disease. In the absence of both
atherosclerotic obstruction and demonstrable epicardial cor-
onary artery spasm, the reduced coronary blood ~ow in
response to vasodilatory stimuli and the occasional develop-
ment of objective signs of ischemia are very likely caused by
small vessel disease. The subjective report of a wide vari-
ability of effort tolerance with occasional occurrence of
apparently spontaneous episodes and the objective finding of
variable levels of heart rate at the onset of ST segment
depression during Holter ECG monitoring (15,20) suggest
that the flow-limiting abnormality of small vessels is func-
tional rather than organic. Thus, we believe that the mor-
phologic abnormalities of small vessels observed in some
studies (28,29) represent an associated or secondary phe-
nomenon rather than the actual cause of the disease. Epstein
and Cannon (30) proposed that "the impediment to flow may
be located in the small intramural prearteriolar vessels"
before they give off subepicardial and subendocardial
branches. In their view, the localization of the flow impedi-
ment in intramyocardial vessels before the branching point
of subepicardial vessels is necessary to account for dipyrida-
mole-induced coronary transmural blood flow steal, which
they assume is the cause of myocardial ischemia in their
patients with "microvascular angina" (30).
Abnormal coronary vascular resistance. Although we do
concur with Epstein and Cannon (30) that a prearteriolar
alteration is the most likely cause of abnormal coronary
vascular behavior, we propose a more general model in
which the abnormality resides in a well identified functional
segment of resistive vessels. In our model, the alteration can
involve any site or the whole segment of the arterial vascular
bed, with appreciable resistance to flow proximal to the
segment directly involved in the metabolic regulation of
coronary blood flow (Fig. 1). We also propose that focal,
sustained, compensatory release of adenosine distal to the
most severely constricted prearterioles may cause persistent
chest pain, possibly even in the absence of myocardial
ischemia.
Distribution of Resistance in the Coronary
Vascular Bed
Functional components of coronary artery bed. The coro-
nary artery bed is usually considered to be composed of two























functional components: I) conductive vessels that offer a
negligible resistance to blood flow, functioning as a bellows
by storing blood during systole (31) and dilating when flow
increases by a flow-dependent local release of endothelium-
derived relaxing factor to reduce intimal shear stress forces
(32); and 2) resistive vessels responsible for the regulation of
myocardial perfusion. However, considering resistive ves-
sels as a single functional vascular segment appears rather
simplistic. Coronary vascular resistance is distributed from
small epicardial coronary branches to capillaries, as indi-
cated by the gradual continuous pressure decrease between
these two extremes (33,34). Yet, within this resistive seg-
ment, vessels of different caliber may exhibit opposite re-
sponses to the same vasoactive stimulus (35).
Resistive vessels and metabolic regulation of myocardial
blood flow. We believe that a functional separation of those
resistive vessels not directly involved in the metabolic
regulation of myocardial blood flow from those directly
exposed to the effects of myocardial metabolites is important
to understand the principles that regulate coronary blood
flow. Although it is certain that epicardial coronary vessels
as well as the larger intramural branches are not directly
involved in the process of metabolic autoregulation of flow,
the type and size of vessels involved in the metabolic
regulation of flow cannot be defined histologically (36,37). If
the findings obtained in subepicardial vessels by direct
visualization can be extrapolated across the whole wall
thickness, metabolic regulation of flow appears to be con-






Figure I. Schematic representation of a conduit coronary artery and
prearteriolar and arteriolar vessels with patchily distributed prear-
teriolar constriction in control conditions (A, upper panel) and
during arteriolar vasodilation (B, upper panel). In this functional
classification, conduit coronary arteries do not have appreciable
flow resistance, arteriolar vessels are responsible for the metabolic
autoregulation of coronary blood flow and prearteriolar vessels are
those segments interposed between conductive arteriolar vessels
with appreciable coronary flow resistance that are responsible for
maintaining perfusion pressure at the origin of arterioles within
optimal levels. The vasodilatory reserve of arterioles distal to
constricted prearteriolar vessels is reduced because they are already
dilated to preserve rest flow.
In conduit coronary arteries, the pressure remains similar to
aortic pressure, but decreases progressively across prearteriolar
vessels in proportion to their degree of constriction (A, lower panel).
During metabolic or pharmacologic arteriolar vasodilation, the
pressure drop increases only slightly distal to some prearteriolar
vessels (ai' az, bz) because vasodilation related to flow-mediated
release of endothelium derived relaxing factor compensates nearly
completely for the increased flow. The pressure drop increases
markedly across more constricted prearteriolar vessels (b l , c., cz)
(B, lower panel). Steal can develop when an increase in flow through
Cz causes a pressure decrease at the branching point distal to the
constricted segment c, so that the driving pressure becomes insuf-
ficient to perfuse adequately the most constricted branch C1 and
blood flow (as indicated by arrows) can become lower than during
rest conditions. The possibility of flow steal is greatly enhanced if
branch Cz perfuses subepicardial layers of the ventricular wall with
a greater flow reserve and if branch c I perfuses the subendocardial
layers with a smaller flow reserve. At the end of the prearteriolar
vessels with the most marked increase in tone (b l ), intravascular
pressure may become insufficient to maintain lumen patency, result-
ing in vessel collapse.
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50% of total coronary vascular resistance would reside
proximal to this site (36). In the absence of precise anatomic
criteria, we propose a functional definition of arteriolar and
prearteriolar vessels.
Functional definition of arteriolar and prearteriolar ves-
sels. Arteriolar vessels are those vessels responsible for the
continuous physiologic matching of coronary blood flow to
myocardial oxygen consumption. The function of arteriolar
vessels is to regulate flow to maintain the composition of
intracellular myocardial fluid within optimal limits for its
contractile function. This regulatory mechanism seems to be
largely the result of the dynamic equilibrium between diffus-
ible vasodilatory metabolites produced by myocytes and
their washout by blood flow, perhaps with the contribution
of tissue oxygen and carbon dioxide tension (31). Adenosine
seems to be an important physiologic mediator of this
autoregulatory mechanism (39). Within each layer of the
myocardium, flow through arterioles depends on their tone,
extravascular resistance and, when they are maximally
dilated, the perfusion pressure at their origin. In turn, the
maintenance of this pressure within an optimal operational
range depends on prearteriolar resistance.
Prearteriolar vessels are those vessels with significant
resistance to flow interposed between conductive coronary
arteries and arteriolar vessels. The function of prearteriolar
vessels is to maintain pressure at the origin of arteriolar
vessels within an optimal operational range. This is achieved
by 1) constricting when aortic pressure increases and dilating
when it decreases; and 2) dilating when coronary flow
increases above rest levels. The physiologic changes in tone
of prearteriolar vessels when aortic pressure varies are likely
to be primarily maintained by the myogenic regulation of
smooth muscle tone (40). Only when aortic pressure de-
creases to very low levels does dilation of arterioles (38)
intervene to compensate for the inevitable decrease in per-
fusion pressure and maintain normal flow. The dilation of
prearteriolar vessels during metabolic autoregulation of flow
is likely to be primarily related to flow-mediated local release
of endothelial-derived resistance factor (32). Both myogenic
and metabolic autoregulation can be modulated by neural
and humoral stimuli, which appear to have remarkably
different effects in successive segments of the arterial bed,
even on the microvascular level (35).
Hemodynamic Consequences of Abnormal
Prearteriolar Constriction
Even a small amount of constriction of prearteriolar
vessels, or the failure to dilate when flow increases, would
require a considerable compensatory arteriolar vasodilation
to maintain adequate myocardial perfusion. Although ade-
quately compensated by distal arteriolar vasodilation, an
increase in prearteriolar resistance would have three impor-
tant interrelated consequences: 1) A reduction of coronary
flow reserve, as a fraction of the available arteriolar dilating
capacity, must already be utilized at rest. 2) A reduction in
pressure at the origin of arteriolar vessels, because accord-
ing to the general relation: flow = pressure gradient/
resistance, an approximately linear increase in the pressure
gradient is necessary to compensate for the increased prear-
teriolar resistance to maintain rest flow. Therefore, the
pressure gradient between the aorta and the origin of arteri-
olar vessels must approximately double if resistance across
prearteriolar vessels doubles and flow remains constant. 3) A
sustained increase in interstitial adenosine concentration
(which may in turn be responsible for the occurrence of
anginal pain).
Mechanisms of Impaired Coronary
Blood Flow
The only consistent finding in syndrome X seems to be an
impaired coronary vasodilator response, which was ob-
served by different investigators using different techniques
(5,7,14,23). In contrast myocardial ischemia was convinc-
ingly documented in only a minority of patients (6-14).
Prearteriolar constriction. We propose that the vascular
abnormality responsible for these findings is located in
prearteriolar vessels as just defined (Fig. 1). The abnormal
constriction of prearteriolar vessels is likely to be patchily
distributed and impair arteriolar blood flow more in the inner
than in the outer layers of the ventricular wall; a higher
extravascular pressure is present in the inner myocardial
layers, thus requiring a higher pressure to oppose extramural
compressive forces and cause prompt diastolic reopening of
the vessels (31). The inner myocardial layers are also more
likely to develop ischemia because they have a higher
myocardial oxygen consumption than the outer layers.
Distal to the most intensely constricted prearterioles,
ischemia may develop either at rest or when myocardial
oxygen consumption increases. During effort, ischemia may
develop as a result of two factors that can operate in
combination: 1) increase in myocardial oxygen consumption
not matched by an adequate increase in coronary blood flow
because of the reduced arteriolar vasodilatory reserve; and
2) arteriolar vasodilation with consequent reduction in in-
traluminal distending pressure, which may become insuffi-
cient to oppose extramural pressure.
Transmural blood flow steal. In our model, as in the
model proposed by Epstein and Cannon (30), transmural
myocardial blood flow steal can develop during metabolic or
pharmacologic arteriolar dilation if a substantial fraction of
prearteriolar resistance is located proximal to the origin of
arterioles in the subepicardial layers and would be enhanced
by an increase in the resistance interposed between the
origins of subepicardial and subendocardial arterioles. In our
model, however, steal could occur even in the same myo-
cardial layer if a marked pressure decrease occurs proximal
to the branching point of two branches with a markedly
different degree of constriction. Moreover, metabolic or
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pharmacologic arteriolar vasodilation could impair flow
through a different mechanism, namely a reduction in lumi-
nal diameter and even total occlusion in the terminal portion
of the most constricted prearterioles as a result of the
luminal instability created by the combination of increased
vasomotor tone and decreased distending pressure (41,42).
Thus, arteriolar vasodilation could initiate a vicious cycle
that would prolong the impairment of flow and duration of
myocardial ischemia.
Mechanisms of Anginal Pain
Adenosine as a mediator of anginal pain. We recently
demonstrated (43) that in patients with angina, intracoronary
infusion of adenosine causes anginal pain similar to that
experienced by these patients during daily life. We also
observed that theophylline, an adenosine antagonist, re-
duces the intensity of spontaneous anginal pain. These
findings lend objective support to the hypothesis proposed
by Sylven et al. (44) that adenosine is a mediator of anginal
pain, which is also supported by the observation that appli-
cation of adenosine to human skin blisters causes severe
pain (45). Because our results (43) showed that only adeno-
sine concentrations greater than those required to produce
maximal coronary vasodilation are algogenic, a constriction
that elicits maximal compensatory dilation seems necessary
to cause an adequate algogenic stimulus.
Adenosine and anginal pain in syndrome X. The demon-
stration that adenosine can be a chemical mediator of anginal
pain could explain the discrepancy between the severity of
angina and the scarcity of objective ischemic signs in pa-
tients with syndrome X compared with those with epicardial
coronary artery obstructions. In the latter, the resistance
created by epicardial coronary stenoses is compensated for
by a decrease in vascular resistance shared by all distal
arterioles. When coronary flow reserve is exhausted, wide-
spread myocardial ischemia develops in the whole region
supplied by the stenotic vessel. Thus, major impairment of
cardiac function causes an unstable hemodynamic situation
that either regresses or evolves rapidly as a result of a
vicious cycle related to increased wall stiffness and diastolic
pressure. Conversely, in the presence of a patchily distrib-
uted and sparse prearteriolar constriction, the local concen-
tration of adenosine may become sufficient to stimulate
cardiac afferent nerves in the absence of impairment of
overall cardiac function. The potential positive feedback
mechanisms triggered by arteriolar vasodilation and a de-
crease in distending pressure, leading to further constriction
at the distal end of prearterioles and a further compensatory
increase in adenosine concentration, could explain the pro-
longed pain experienced by patients with syndrome X.
Chest pain in absence of ischemia: role of adenosine. It is
possible that in syndrome X, chest pain might occur in the
absence of ischemia, just as during intracoronary infusion of
adenosine. The possibility that a focal increase in adenosine
concentration distal to the most severely constricted arteri-
oles might cause pain in the absence of ischemia is suggested
by observations in open chest dogs. L'Abbate et al. (46)
showed that the effects of a steady-state adenosine infusion
are time-dependent, so that coronary flow values 100%
greater than those produced by peak reactive hyperemia can
be attained after 30 min of adenosine infusion. It would be
conceivable, therefore, that in the absence of impaired
cardiac function, a sustained focal release of adenosine
could result in sufficient prearteriolar dilation to prevent
myocardial ischemia.
Enhanced perception of painful stimuli. The patchy dis-
tribution of markedly elevated adenosine concentrations
caused by the most constricted prearteriolar vessels might
also contribute to making the algogenic stimulation supra-
liminal, if the perception of pain depends on a spatially
inhomogeneous stimulation of cardiac afferent polimodal
receptors (47). Finally, another possible component of the
discrepancy between the severity of pain and the minimal
objective alteration of cardiac function in patients with
syndrome X seems related to an enhanced perception of
potentially painful stimuli (48-50).
Possible Causes of Abnormal
Prearteriolar Constriction
Insufficient vasodilation or inappropriate vasoconstriction.
The cause of prearteriolar coronary constriction may be
related to a local deficit of flow-mediated endothelium-
derived relaxing factor production (32) so that prearterioles
do not dilate when arterioles dilate and cause flow to
increase, resulting in a large pressure decrease at the end of
prearteriolar vessels. Alternatively, it could be related to a
primary inappropriate constriction of the smooth muscle that
could result from either a very specific powerful neural
stimulus or a nonspecific hyperreactivity to a variety of
constrictor stimuli (51) similar to that responsible for seg-
mental epicardial coronary artery spasm (52,53). Our obser-
vations that neuropeptide Y (54) and endothelin (55) can
cause massive transmural myocardial ischemia in the ab-
sence of detectable epicardial coronary artery constriction
provide evidence that distal coronary vessels have the
potential to constrict to such an extent as to completely
overpower metabolic autoregulation. Alpha-adrenergic stim-
ulation was also shown (56) to cause hypoperfusion resulting
in ischemia, but only in the presence of a critical coronary
stenosis.
Resetting of myogenic control of prearteriolar tone. Alter-
natively, the abnormality might be related to a resetting of
the myogenic control (40) of tone in prearteriolar vessels,
which, superimposed on the marked physiologic spatial
microheterogeneity of myocardial perfusion (31), could re-
sult in patchily distributed hypoperfusion. There is no pre-
cise evidence for this mechanism, but impaired coronary
flow reserve has been reported (57,58) in hypertensive
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patients in the absence of myocardial hypertrophy in asso-
ciation with angina and normal coronary arteries.
Segmental versus generalized distribution of prearteriolar
abnormalities. It is still unknown whether the alteration of
prearteriolar vessels in syndrome X is distributed uniformly
in the ventricular walls or whether it is regional. Asegmental
abnormality corresponding to the territory of a major coro-
nary artery branch would be compatible with a segmental
neural abnormality because the efferent sympathetic inner-
vation of the heart has a segmental distribution that parallels
that of major arterial branches (59). Conversely, distribution
of the abnormality to the entire coronary arterial bed would
suggest a generalized alteration.
Clinical implications. The causes of prearteriolar coro-
nary constriction need not be the same in all patients; thus,
the evolution of the disease may vary despite a similar
clinical presentation. However, in most cases these causes
must be stable because the disease tends to remain stable for
years. Understanding the causes of the abnormal prearteri-
olar constriction is important because the beneficial effects
of traditional antianginal drugs in patients with syndrome X
are small and difficult to demonstrate in controlled trials.
Beta-adrenergic blockers are much less effective in patients
with syndrome X than in those with chronic stable angina
and coronary artery disease (4,60-62), suggesting that a
reduction in myocardial oxygen consumption is not an
effective means of preventing or compensating for the un-
derlying vasomotor abnormality. Calcium channel antago-
nists and nitrates produce inconsistent responses (20), sug-
gesting that at the doses currently used, drugs that reduce
vascular smooth muscle tone nonspecifically are ineffective
in preventing the abnormal segmental constriction of those
prearteriolar vessels most severely involved. Clonidine and
prazosin are also ineffective in improving symptoms or
ischemic ST segment changes (63). In contrast, the fact that
aminophylline was found (64) to be effective in improving
symptoms and ST segment ischemic changes is compatible
with an important role of excessive myocardial adenosine
release.
Conclusions
On the basis of available information, it would seem
reasonable to postulate that a dynamic inappropriate con-
striction of prearteriolar vessels can cause a limitation of
coronary flow reserve, anginal pain and possibly myocardial
ischemia. Prearteriolar constriction need not be segmentally
localized in intramyocardial vessels proximal to the origin of
subepicardial arterioles and is likely to be nonuniform, with
only a minority of prearteriolar vessels very intensely con-
stricted. During increased cardiac activity, focal myocardial
ischemia can result from the reduction in coronary flow
reserve because some flow reserve is utilized during rest
conditions to compensate for the prearteriolar constriction.
During increased myocardial blood flow, focal myocardial
ischemia can also result from the decrease in pressure at the
terminal end of the most intensely constricted prearterioles
because distending pressure may become insufficient to
adequately oppose extravascular compressive forces and
maintain subendocardial myocardial perfusion and lumen
stability. Because prearteriolar coronary constriction stimu-
lates the local release of adenosine, a focal increase in
myocardial adenosine concentration, if intense and pro-
longed, could cause anginal pain, even in the absence of
detectable signs of myocardial ischemia since adenosine
appears to be an adequate chemical stimulus for cardiac
pain.
This hypothesis could explain the wide spectrum of clin-
ical presentations ofpatients with syndrome X. At one end
of the spectrum, the involvement of a large number of
prearteriolar vessels would explain the reduced coronary
flow reserve and the presence of myocardial ischemia ob-
served in some patients. At the other, the involvement of a
very limited number of prearterioles could explain the oc-
currence of pain in the absence of detectable signs of
ischemia and perhaps even in the absence of a detectable
reduction in total coronary flow reserve. The difference in
response to treatment and in evolution may be related to
different underlying causes of the prearteriolar vasoconstric-
tion. The evolution in some patients to dilated cardiomyop-
athy (65) could be related to intense forms of small vessel
spasm, similar to that observed in the Syrian hamster model
(66).
The study of the mechanisms of inappropriate constric-
tion of coronary prearteriolar vessels in syndrome X may
also be relevant to the understanding of distal coronary
vessel constriction in acute (67) and chronic (68) ischemic
syndromes associated with epicardial coronary artery dis-
ease.
Our hypothesis is intended to explain the clinical features
of the syndrome and stimulate further research into the
mechanisms of this common clinical syndrome to develop
diagnostic criteria that would allow a positive identification
of the cardiac origin of the pain and effective treatment.
Meanwhile the term syndrome X should remain to remind us
of our ignorance.
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